Sepsis and thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 559-566

  Levi, Marcel ^a   Schultz, Marcus ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

heparin; inflammation; sepsis; thrombophilia; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; DROTRECOGIN; EPIDERMAL GROWTH FACTOR; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RIVAROXABAN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOPSY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFLAMMATION; INTENSIVE CARE UNIT; META ANALYSIS; MORTALITY; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 84879112208     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343894     Document Type: Article

References (95)

1. Wheeler A. P., Bernard G. R. Treating patients with severe sepsis. N Engl J Med: 1999; 340 3 207 214
2. Martin G. S., Mannino D. M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med: 2003; 348 16 1546 1554
3. Angus D. C., Linde-Zwirble W. T., Lidicker J., Clermont G., Carcillo J., Pinsky M. R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med: 2001; 29 7 1303 1310
4. Levi M. The coagulant response in sepsis. Clin Chest Med: 2008; 29 4 627 642, viii
5. Levi M., van der Poll T., Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med: 2012; 70 3 114 120
6. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med: 1999; 341 8 586 592
7. Colman R. W., Robboy S. J., Minna J. D. Disseminated intravascular coagulation: a reappraisal. Annu Rev Med: 1979; 30 359 374
8. Miller D. L., Welty-Wolf K., Carraway M. S., et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol: 2002; 26 6 650 658
9. Levi M., de Jonge E., van der Poll T., ten Cate H. Disseminated intravascular coagulation. Thromb Haemost: 1999; 82 2 695 705
10. Ratnoff O. D., Nebehay W. G. Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. Ann Intern Med: 1962; 56 627 632
11. Levi M., Keller T. T., van Gorp E., ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res: 2003; 60 1 26 39
12. Robboy S. J., Major M. C., Colman R. W., Minna J. D. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. Hum Pathol: 1972; 3 3 327 343
13. Shimamura K., Oka K., Nakazawa M., Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med: 1983; 107 10 543 547
14. Coalson J. J. Pathology of sepsis, septic shock, and multiple organ failure. In: Perspective on Sepsis and Septic Shock. Fullerton, CA Society of Critical Care Medicine: 1986; 27 59
15. Creasey A. A., Chang A. C., Feigen L., Wün T. C., Taylor F. BJ Jr, Hinshaw L. B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest: 1993; 91 6 2850 2860
16. Kessler C. M., Tang Z., Jacobs H. M., Szymanski L. M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood: 1997; 89 12 4393 4401
17. Taylor F. BJ Jr, Chang A., Ruf W., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock: 1991; 33 3 127 134
18. Taylor F. BJ Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest: 1987; 79 3 918 925
19. Welty-Wolf K. E., Carraway M. S., Miller D. L., et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med: 2001; 164 10, Pt 1 1988 1996
20. Fourrier F., Chopin C., Goudemand J., et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest: 1992; 101 3 816 823
21. Dhainaut J. F., Yan S. B., Joyce D. E., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost: 2004; 2 11 1924 1933
22. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med: 2000; 28 6 1871 1876
23. Strauss R., Wehler M., Mehler K., Kreutzer D., Koebnick C., Hahn E. G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med: 2002; 30 8 1765 1771
24. Oppenheim-Eden A., Glantz L., Eidelman L. A., Sprung C. L. Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors. Intensive Care Med: 1999; 25 1 63 67
25. Stéphan F., Hollande J., Richard O., Cheffi A., Maier-Redelsperger M., Flahault A. Thrombocytopenia in a surgical ICU. Chest: 1999; 115 5 1363 1370
26. Akca S., Haji-Michael P., de Mendonça A., Suter P. M., Levi M., Vincent J. L. Time course of platelet counts in critically ill patients. Crit Care Med: 2002; 30 4 753 756
27. Levi M., van der Poll T., ten Cate H., van Deventer S. J. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest: 1997; 27 1 3 9
28. Levi M., van der Poll T., Buller H. R. Bidirectional relationship between coagulation and inflammation. Circulation: 2004; 109 22 2698 2704
29. Aird W. C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med: 2001; 29 (7, Suppl): S28 S34, discussion S34-S35
30. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood: 1990; 76 12 2520 2526
31. van der Poll T., Büller H. R., ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med: 1990; 322 23 1622 1627
32. Levi M., ten Cate H., Bauer K. A., et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest: 1994; 93 1 114 120
33. Biemond B. J., Levi M., ten Cate H., et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost: 1995; 73 2 223 230
34. Zimmerman G. A., McIntyre T. M., Prescott S. M., Stafforini D. M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med: 2002; 30 (5, Suppl): S294 S301
35. Shebuski R. J., Kilgore K. S. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther: 2002; 300 3 729 735
36. Vary T. C., Kimball S. R. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol: 1992; 262 2, Pt 1 C445 C452
37. Seitz R., Wolf M., Egbring R., Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol: 1989; 43 1 22 28
38. Opal S. M., Kessler C. M., Roemisch J., Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med: 2002; 30 (5, Suppl): S325 S331
39. Mesters R. M., Mannucci P. M., Coppola R., Keller T., Ostermann H., Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. [see comments] Blood: 1996; 88 3 881 886
40. Esmon C. T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med: 2002; 196 5 561 564
41. Zushi M., Gomi K., Yamamoto S., Maruyama I., Hayashi T., Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem: 1989; 264 18 10351 10353
42. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem: 1996; 271 28 16603 16608
43. Taylor F. B. Jr, Peer G. T., Lockhart M. S., Ferrell G., Esmon C. T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood: 2001; 97 6 1685 1688
44. Eckle I., Seitz R., Egbring R., Kolb G., Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler: 1991; 372 11 1007 1013
45. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med: 1986; 163 3 740 745
46. Faust S. N., Levin M., Harrison O. B., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med: 2001; 345 6 408 416
47. Taylor F. BJ Jr, Dahlback B., Chang A. C., et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood: 1995; 86 7 2642 2652
48. Levi M., Dörffler-Melly J., Reitsma P. H., et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood: 2003; 101 12 4823 4827
49. Broze G. J. Jr, Girard T. J., Novotny W. F. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry: 1990; 29 33 7539 7546
50. de Jonge E., Dekkers P. E., Creasey A. A., et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood: 2000; 95 4 1124 1129
51. Gando S., Kameue T., Morimoto Y., Matsuda N., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med: 2002; 30 8 1729 1734
52. Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med: 2002; 30 8 1914 1915
53. Schouten M., van 't Veer C., van der Poll T., Levi M. Effect of the factor V Leiden mutation on the incidence and outcome of severe infection and sepsis. Neth J Med: 2012; 70 7 306 310
54. Middeldorp S., Levi M. Thrombophilia: an update. Semin Thromb Hemost: 2007; 33 6 563 572
55. Inbal A., Kenet G., Zivelin A., et al. Purpura fulminans induced by disseminated intravascular coagulation following infection in 2 unrelated children with double heterozygosity for factor V Leiden and protein S deficiency. Thromb Haemost: 1997; 77 6 1086 1089
56. Dogan Y., Aygun D., Yilmaz Y., et al. Severe protein S deficiency associated with heterozygous factor V Leiden mutation in a child with purpura fulminans. Pediatr Hematol Oncol: 2003; 20 1 1 5
57. al-Ismail S., Collins P., Najib R., James-Ellison M., O'Hagan M. Postinfection purpura fulminans in a patient heterozygous for prothrombin G20210A and acquired protein S resistance. Pediatr Hematol Oncol: 1999; 16 6 561 564
58. Woods C. R., Johnson C. A. Varicella purpura fulminans associated with heterozygosity for factor V Leiden and transient protein S deficiency. Pediatrics: 1998; 102 5 1208 1210
59. Saçkesen C., Seçmeer G., Gürgey A., et al. Homozygous Factor V Leiden mutation in a child with meningococcal purpura fulminans. Pediatr Infect Dis J: 1998; 17 1 87
60. Hofstra J. J., Schouten M., Levi M. Thrombophilia and outcome in severe infection and sepsis. Semin Thromb Hemost: 2007; 33 6 604 609
61. Texereau J., Pene F., Chiche J. D., Rousseau C., Mira J. P. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med: 2004; 32 (5, Suppl): S313 S319
62. Lay A. J., Liang Z., Rosen E. D., Castellino F. J. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest: 2005; 115 6 1552 1561
63. Jalbert L. R., Rosen E. D., Moons L., et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest: 1998; 102 8 1481 1488
64. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med: 2010; 38 (2, Suppl): S26 S34
65. Kondaveeti S., Hibberd M. L., Booy R., Nadel S., Levin M. Effect of the Factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J: 1999; 18 10 893 896
66. Kerlin B. A., Yan S. B., Isermann B. H., et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood: 2003; 102 9 3085 3092
67. Schouten M., van't Veer C., Roelofs J. J., Levi M., van der Poll T. Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study. Crit Care: 2010; 14 4 R145
68. Brüggemann L. W., Schoenmakers S. H., Groot A. P., Reitsma P. H., Spek C. A. Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice. Crit Care Med: 2006; 34 8 2201 2206
69. Schouten M., van der Sluijs K. F., Roelofs J. J., Levi M., Van't Veer C., van der Poll T. Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza. Eur Respir J: 2010; 36 6 1346 1354
70. Elmas E., Suvajac N., Jilma B., Weiler H., Borggrefe M., Dempfle C. E. Factor V Leiden mutation enhances fibrin formation and dissolution in vivo in a human endotoxemia model. Blood: 2010; 116 5 801 805
71. Bernard G. R., Vincent J. L., Laterre P. F., et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med: 2001; 344 10 699 709
72. Bernard G. R., Margolis B. D., Shanies H. M., et al. Extended Evaluation of Recombinant Human Activated Protein C United States Investigators Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest: 2004; 125 6 2206 2216
73. Yan S. B., Nelson D. R. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med: 2004; 32 (5, Suppl): S239 S246
74. Benfield T. L., Dahl M., Nordestgaard B. G., Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis: 2005; 192 10 1851 1857
75. Benfield T., Ejrnaes K., Juul K., et al. Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study. Crit Care: 2010; 14 2 R28
76. du Toit H. J., Coetzee A. R., Chalton D. O. Heparin treatment in thrombin-induced disseminated intravascular coagulation in the baboon. Crit Care Med: 1991; 19 9 1195 1200
77. Feinstein D. I. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood: 1982; 60 2 284 287
78. Dörffler-Melly J., de Jonge E., Pont A. C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet: 2002; 359 9309 849 850
79. Vlasuk G. P., Bergum P. W., Bradbury A. E., Loynds P., Mant T. G., Rote W. E. Clinical evaluation of rNAPc2, an inhibitor of the fVIIa/tissue factor coagulation complex. Am J Cardiol: 1997; 80 66S
80. Abraham E., Reinhart K., Svoboda P., et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med: 2001; 29 11 2081 2089
81. Abraham E., Reinhart K., Opal S., et al. OPTIMIST Trial Study Group Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA: 2003; 290 2 238 247
82. Levi M., Lowenberg E., Meijers J. C. Recombinant anticoagulant factors for adjunctive treatment of sepsis. Semin Thromb Hemost: 2010; 36 5 550 557
83. Warren B. L., Eid A., Singer P., et al. KyberSept Trial Study Group Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA: 2001; 286 15 1869 1878
84. Kienast J., Juers M., Wiedermann C. J., et al. KyberSept investigators Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost: 2006; 4 1 90 97
85. Bernard G. R., Ely E. W., Wright T. J., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med: 2001; 29 11 2051 2059
86. Ranieri V. M., Thompson B. T., Barie P. S., et al. PROWESS-SHOCK Study Group Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med: 2012; 366 22 2055 2064
87. Saito H., Maruyama I., Shimazaki S., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost: 2007; 5 1 31 41
88. Aikawa N., Shimazaki S., Yamamoto Y., et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock: 2011; 35 4 349 354
89. Cook D. J., Crowther M. A. Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med: 2010; 38 (2, Suppl): S76 S82
90. Dörffler-Melly J., de Jonge E., Pont A. C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet: 2002; 359 9309 849 850
91. Priglinger U., Delle Karth G., Geppert A., et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med: 2003; 31 5 1405 1409
92. Rommers M. K., Van der Lely N., Egberts T. C., van den Bemt P. M. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care: 2006; 10 3 R93
93. Haas C. E., Nelsen J. L., Raghavendran K., et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma: 2005; 59 6 1336 1343, discussion 1343-1344
94. Cook D., Douketis J., Meade M., et al. Canadian Critical Care Trials Group Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care: 2008; 12 2 R32
95. Cohen A. T., Spiro T. E., Büller H. R., et al. MAGELLAN Investigators Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med: 2013; 368 6 513 523